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Abstract
Background: Recent evidence suggests that drugs targeting Kv7 channels could be used to modulate vascular function
and blood pressure. Here, we studied whether Kv7 channel inhibitors can be utilized to stabilize hemodynamics and
reduce resuscitation fluid requirements after hemorrhagic shock.
Methods: Anesthetized male Sprague-Dawley rats were instrumented with arterial and venous catheters for blood
pressure monitoring, hemorrhage and fluid resuscitation. Series 1: Linopirdine (Kv7 channel blocker, 0.1–6 mg/kg) or
retigabine (Kv7 channel activator, 0.1–12 mg/kg) were administered to normal animals. Series 2: Animals were
hemorrhaged to a MAP of 25 mmHg for 30 min, followed by fluid resuscitation with normal saline (NS) to a
MAP of 70 mmHg until t = 75 min. Animals were treated with single bolus injections of vehicle, linopirdine (1–6 mg/kg),
XE-991 (structural analogue of linopirdine with higher potency for channel blockade, 1 mg/kg) prior to fluid resuscitation.
Series 3: Animals were resuscitated with NS alone or NS supplemented with linopirdine (1.25–200 μg/mL). Data were
analyzed with 2-way ANOVA/Bonferroni post-hoc testing.
Results: Series 1: Linopirdine transiently (10–15 min) and dose-dependently increased MAP by up to 15%. Retigabine
dose-dependently reduced MAP by up to 60%, which could be reverted with linopirdine. Series 2: Fluid requirements to
maintain MAP at 70 mmHg were 65 ± 34 mL/kg with vehicle, and 57 ± 13 mL/kg, 22 ± 8 mL/kg and 22 ± 11 mL/kg with
intravenous bolus injection of 1, 3 and 6 mg/kg linopirdine, respectively. XE-991 (1 mg/kg), reduced resuscitation
requirements comparable to 3 mg/kg linopirdine.
Series 3: When resuscitation was performed with linopirdine-supplemented normal saline (NS), fluid requirements
to stabilize MAP were 73 ± 12 mL/kg with NS alone and 72 ± 24, 61 ± 20, 36 ± 9 and 31 ± 9 mL/kg with NS supplemented
with 1.25, 6.25, 12.5 and 200 μg/mL linopirdine, respectively.
Conclusions: Our data suggest that Kv7 channel blockers could be used to stabilize blood pressure and reduce fluid
resuscitation requirements after hemorrhagic shock.
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Background
In the United States trauma is the 5th leading cause of
death in the overall population and the leading cause of
death among those aged 5–44 [1]. Hemorrhagic shock is
the major cause of potentially preventable death after
accidental injuries and accounts for over 40% of deaths
within the first 24 h in trauma patients [2]. Adequate
fluid resuscitation to compensate for intravascular volume
deficits and to support organ perfusion is an essential
cornerstone in the treatment of patients with traumatic-
hemorrhagic shock [3]. High-volume fluid resuscitation,
however, carries the well-recognized risk of fluid overload,
which can lead to third-spacing of fluids into tissues,
edema formation, coagulopathy, abdominal compartment
syndrome, or acute lung injury, and significantly con-
tributes to mortality and morbidity in critically ill pa-
tients [4–6]. Furthermore, in patients who fail to meet
blood pressure targets during fluid resuscitation, vaso-
pressors are often added at the discretion of the health
care provider [5]. Vasopressors, however, can have sig-
nificant adverse effects and their use is limited by
vasoconstrictor-induced ischemia. Although pressure-
support resuscitation of hemorrhagic shock with arginine
vasopressin (aVP) has been discussed as a possible strategy
to improve outcomes [7, 8], drugs which stabilize cardio-
vascular function, reduce resuscitation fluid requirements
and lack significant intrinsic vasopressor activity are not
available. Such drugs, however, are highly desirable as they
have the potential to reduce morbidity and mortality asso-
ciated with high-volume fluid resuscitation and vasopres-
sor treatment.
Kv7 voltage-activated potassium channels are import-
ant regulators of the membrane potential in excitable
cells, such as neurons, cardiomyocytes or smooth muscle
cells [9–12]. The expression pattern of Kv7 channels is
very similar across species, with Kv7.1, Kv7.4 and Kv7.5
being ubiquitously expressed in every arterial bed so far
examined [10].
Kv7 channels display an activation threshold near the
resting membrane potential and generate outwardly
rectifying potassium currents (M-current), which sta-
bilize resting membrane potential and suppress cell
excitability [10].
Preclinical and clinical drug development has so far
focused on the therapeutic potential of Kv7 channel
modulators in neurological diseases. Several drugs tar-
geting Kv7 channels have been developed. Flupirtine, a
Kv7 channel activator, has been approved by the European
Medicines Agency as a non-opioid analgesic more than 25
years ago [13]. The Kv7 channel activator retigabine (also
known as ezogabine), a structural analog of flupirtine, re-
ceived approval by the US Food and Drug Administration
and the European Medicines Agency for the treatment of
partial-onset seizures in adults [14]. Furthermore, the Kv7
channel inhibitor linopirdine has been tested as a
cognition-enhancing drug in Alzheimer’s disease, but
failed to demonstrate clinically meaningful improvements
of cognitive function [15].
More recently, Kv7 channels have been recognized as
important regulators of vascular smooth muscle func-
tion. Several lines of evidence suggest that drugs targeting
Kv7 channels could be useful to modulate vascular re-
activity and blood pressure in various pathological condi-
tions [10, 16]. While symptomatic hypotension has been
reported as an adverse event after oral administration of
high doses of retigabine in phase I clinical trials [17], reti-
gabine has demonstrated the beneficial effect of reducing
acute hypertension induced by co-administration of angio-
tensin II plus arginine vasopressin in rats [18]. Further-
more, the Kv7 channel activator flupirtine has been
reported to reduce pulmonary hypertension in rodent
models [19, 20]. Whether Kv7 channel blockade could be
useful to improve hemodynamics and stabilize blood pres-
sures in hypotensive disease processes, however, remains
unknown. Thus, we performed a pilot study to assess the
effects of Kv7 channel modulators during fluid resuscita-
tion after hemorrhagic shock in a Wigger’s model of
fixed-pressure hemorrhage in rats.
Methods
All procedures were performed according to National
Institutes of Health Guidelines for Use of Laboratory
Animals and were approved by the Institutional Animal
Care and Use Committee of Loyola University Chicago.
Male Sprague-Dawley rats (300–350 g) were purchased
from Harlan. Rats were anesthetized with 1.5% isoflurane/
100% oxygen. At this dose, rats did not respond to
noxious stimuli, but were able to breathe spontaneously.
The femoral artery was cannulated with a 22-gauge angio-
catheter for arterial blood pressure monitoring and blood
withdrawal. The femoral vein was cannulated with 1.5-
french tubing for fluid and drug administration. After
instrumentation, 5–15 min of stable blood pressure re-
cordings were obtained. Core body temperature was
maintained using warming lamps. The following series of
experiments were then performed:
Series 1: Administration of Kv7 channel modulators
in normal animals.
In a first set of experiments, animals (n = 3)
received 5 intravenous bolus injections of increasing
doses of linopirdine (Tocris Bioscience, Bristol, UK,
0.1 – 6 mg/kg in 0.5 mL of NS). In a second set of
experiments, animals (n = 3) received 6 intravenous
bolus injections of increasing doses of retigabine
(Alomone Labs, Jerusalem, Israel, 0.1–12 mg/kg in
0.5 mL of NS) followed by an intravenous bolus
injection of 6 mg/kg linopirdine (in 0.5 mL of NS)
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in 15 min intervals. Heart rates (HR), systolic arterial
blood pressures (SBP), diastolic arterial blood pressures
(DBP) and mean arterial blood pressures (MAP)
were recorded in 10 s - 1 min intervals. At the end
of the experiments, animals were euthanized
(isoflurane inhalation, bilateral pneumothorax).
Series 2: Bolus administration of Kv7 channel
inhibitors during resuscitation from hemorrhagic
shock.
We utilized aWiggers model of fixed-pressure
hemorrhage, as described in detail previously [21].
In brief, animals were hemorrhaged to a MAP of
25 mmHg for 30 min. At t = 30 min, animals were
resuscitated with NS until MAP returned to 70 mmHg.
MAP was then maintained at 70 mmHg by continuous
fluid administration for a total of 45 min, as required.
At the end of the resuscitation period animals were
euthanized (isoflurane inhalation, bilateral pneumothorax).
In a first set of experiments animals received an
intravenous bolus injection of vehicle (0.5 mL NS,
n = 4) or 1 mg/kg (n = 5), 3 mg/kg (n = 3) or 6 mg/kg
(n = 3) linopirdine in 0.5 mL NS at the beginning of
fluid resuscitation (t = 30 min). In a second set of
experiments animals received an intravenous bolus
injection of vehicle (0.5 mL NS, n = 3) or XE-991
(Alomone Labs, 1 mg/kg in 0.5 mL NS, n = 3) at the
beginning of fluid resuscitation (t = 30 min).
Series 3: Linopirdine-supplementation of
resuscitation fluid.
Animals were resuscitated with NS alone (n = 4)
or with NS supplemented with 1.25 μg/mL (n = 4),
6.25 μg/mL (n = 3), 12.5 μg/mL (n = 3) or 200 μg/mL
(n = 6) of linopirdine. SBP, DBP, MAP, blood volumes
hemorrhaged and resuscitation fluid requirements
were recorded in 1 min intervals until t = 30 min
and then in 5 min intervals until the end of the
experiment. At the end of the experiments, animals
were euthanized (isoflurane inhalation, bilateral
pneumothorax) and gross necropsies were performed.
Data analyses and statistics
Data are described as mean ± standard deviation (SD).
Data were analyzed with two-way repeated measures
(mixed model) analysis of variance and Bonferroni
post-hoc tests to correct for multiple testing, as appro-
priate. A two-tailed p < 0.05 was considered significant.
All data were analyzed using the GraphPad-Prism 6
software.
Results
Series 1: Administration of Kv7 channel modulators in
normal animals.
The effects of the Kv7 channel inhibitor linopirdine
on arterial blood pressures in normal animals are
shown in Fig. 1a. At baseline, MAP was 92 ± 2.5
mmHg. Within 5 min after intravenous linopirdine
injection, MAP peaked at 92 ± 2 mmHg, 93 ± 2 mmHg,
95 ± 4 mmHg, 100 ± 2 mmHg and 105 ± 0.6 mmHg
with linopirdine dosages of 0.1 mg/kg, 0.5 mg/kg,
1 mg/kg, 3 mg/kg and 6 mg/kg, respectively. Blood
pressures returned to pre-injection values within
ten to fifteen minutes. Figure 1b shows the blood
pressure effects of the Kv7 channel activator retigabine.
Intravenous retigabine injection dose-dependently
reduced MAP from 91 ± 4 mmHg at baseline to
80 ± 8 mmHg with 0.5 mg/kg retigabine, and to
Fig. 1 Effects of Kv7 channel modulators on blood pressure in normal rats. a. Intravenous injection of increasing doses of linopridine (0.1-6 mg/kg in
0.5 mL normal saline). Arrows indicate time points of drug injection. Open squares: Systolic blood pressure. Grey squares: Diastolic blood pressure.
Black Squares: Mean arterial blood pressure. BP: Blood pressure (mmHg). N = 3. Data are mean ± SD. b. Intravenous injection of increasing doses of
retigabine (0.1-12 mg/kg in 0.5 mL normal saline) followed by an intravenous injection of 6 mg/kg linopirdine in 0.5 mL normal saline. Open squares:
Systolic blood pressure. Grey squares: Diastolic blood pressure. Black Squares: Mean arterial blood pressure. BP: Blood pressure (mmHg). N = 3
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60 ± 5 mmHg, 42 ± 1 mmHg, 37 ± 1 mmHg and
34 ± 2 mmHg with 1 mg/kg, 3 mg/kg, 6mg/kg and
12 mg/kg retigabine, respectively. The duration of
retigabine-induced hypotension increased with
increasing doses. While MAP returned to
pre-injection levels within 15 min when low doses
of retigabine were injected (0.1 – 3 mg/kg), MAP
did not recover to pre-injection values within
15 min at higher doses. Injection of 6 mg/kg
linopirdine antagonized hypotension induced
by 12 mg/kg retigabine.
Series 2: Bolus administration of Kv7 channel
inhibitors during resuscitation from hemorrhagic
shock.
We first tested the effects of single i.v. bolus
injections of various doses of linopirdine after
hemorrhagic shock. As shown in Fig. 2a/b, the
blood volumes hemorrhaged to achieve a MAP
target of 25 mmHg during the 30 min shock period
was comparable in all animals. Linopirdine or vehicle
were injected at the beginning of fluid resuscitation
followed by crystalloid fluid resuscitation to maintain
MAP at 70 mmHg. All animals could be resuscitated
to the MAP resuscitation target. As compared with
vehicle treated animals, linopirdine dose-dependently
reduced fluid resuscitation requirements from
65 ± 34 mL/kg with vehicle to 57 ± 13 mL/kg,
22 ± 8 mL/kg (p < 0.05 vs. vehicle) and 22 ± 11 mL/kg
(p < 0.05 vs. vehicle) with 1 mg/kg, 3 mg/kg and
6 mg/kg linopirdine, respectively (Fig. 2c). To test
whether the resuscitation fluid-sparing effect of
linopirdine can be generalized to other Kv7 channel
inhibitors, we then compared the effects of XE-991
(1 mg/kg), a Kv7 channel inhibitor with higher
potency than linopirdine, with vehicle treated
animals under the same experimental conditions.
The hemorrhage volumes were comparable between
vehicle and XE-991 treated animals and all animals
could be resuscitated to the MAP target (Fig. 3a/b).
As observed for linopirdine, XE-991 significantly
reduced cumulative resuscitation fluid requirements
from 83 ± 16 mL/kg with vehicle treatment to
36 ± 16 mL/kg with XE-991 treatment (Fig. 3c).
Series 3: Linopirdine-supplementation of resuscitation
fluid.
We then evaluated whether, instead of an i.v. bolus
of linopirdine, supplementation of resuscitation fluids
with various concentrations of linopirdine would also
reduce cumulative resuscitation fluid requirements in
the same model (Fig. 4). Similar to the previous
experimental groups, hemorrhage volumes to achieve
a MAP of 25 mmHg during the shock period were
comparable between all groups and all animals could
be resuscitated to a MAP of 70 mmHg. In this set
of experiments, fluid resuscitation requirements were
73 ± 12 mL/kg with NS alone, 72 ± 24 mL/kg with
NS supplemented with 1.25 μg/mL linopirdine and
Fig. 2 Linopirdine reduces resuscitation fluid requirements after
hemorrhagic shock. Animals were hemorrhaged to a mean arterial
blood pressure (MAP) of 25 mmHg for 30 min, followed by fluid
resuscitation to a MAP of 70 mmHg. At the end of the shock period
(t = 30 min), vehicle (n = 4, open squares), 1 mg/kg (n = 5, light grey
squares), 3 mg/kg (n = 3, black squares) or 6 mg/kg (n = 3, open circles)
linopirdine in 0.5 mL normal saline were injected intravenously.
Arrows indicate the time point of drug injection. *: p < 0.05 vs. vehicle.
a. Mean arterial blood pressure (MAP, mmHg). b. Hemorrhage volume
in % of total blood volume (%BV hemorrhage). c. Resuscitation fluid
requirements (mL/kg) to maintain MAP at 70 mmHg
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61 ± 20 mL/kg when NS was supplemented with
6.25 μg/mL linopirdine (p > 0.05 vs. NS alone).
When NS was supplemented with 12.5 μg/mL and
200 μg/mL linopirdine, however, resuscitation
fluid requirements were reduced to 36 ± 9 mL/kg
(p < 0.05 vs. NS alone) and 31 ± 9 mL/kg (p < 0.05 vs.
NS alone), respectively.
We did not observe any macroscopic abnormalities,
such as signs of ischemia, hemorrhage or infection, in
any abdominal or thoracic organ during gross necropsies
of the animals.
Discussion
In the present study, we provide initial pre-clinical evi-
dence suggesting that Kv7 channel inhibitors could be
used to stabilize blood pressure and reduce fluid resus-
citation requirements after hemorrhagic shock. Our
findings on the blood pressure effects of the Kv7 chan-
nel inhibitor linopirdine and the Kv7 channel activator
retigabine in normal Sprague-Dawley rats are in agree-
ment with previous observations in the same strain of
rats and confirm that both drugs dose-dependently
modulate systemic blood pressure in vivo [18, 22]. In
addition, our findings demonstrate that even a high
intravenous bolus dose of linopirdine (6 mg/kg) and a
total intravenous dose of 10.6 mg/kg of linopirdine
administered within 1 h caused only minimal and
short-lived increases in systemic blood pressures. In
combination with the observation that intravenous
injection of comparable doses of linopirdine to male
Wistar rats did not affect systemic blood pressure [23],
these data suggest that systemic vasopressor effects of
linopirdine are consistently small. Despite only modest
effects of acute linopirdine treatment on blood pressure
in normotensive rats, we observed that retigabine-
induced hypotension was instantaneously reverted with
intravenous linopirdine. This finding is in agreement
with urodynamic effects of retigabine and linopirdine
[24] and with the effects of linopirdine on hypotension
induced by kynurenine, a natural tryptophan metabolite
that is thought to activate Kv7 channels and which has
been implicated in the pathophysiology of sepsis [25].
As such, Kv7 channel modulators may provide an alter-
native pharmacological approach for the management
of hypertensive emergencies, in which drugs that per-
mit rapid, titratable and reversible reduction of blood
pressure are highly desirable.
We detected that a single dose of linopirdine at the
beginning of fluid resuscitation from hemorrhagic shock
dose-dependently reduced fluid requirements to stabilize
blood pressure. The observed effects of linopirdine
were saturated at a dose of 3 mg/kg and resulted in
65% reduction of resuscitation fluid requirements. The
Fig. 3 XE-991 reduces resuscitation fluid requirements after hemorrhagic
shock. Animals were hemorrhaged to a mean arterial blood pressure
(MAP) of 25 mmHg for 30 min, followed by fluid resuscitation to a MAP
of 70 mmHg. At the end of the shock period (t = 30 min), vehicle
(n = 3, open squares) or 1 mg/kg XE-991 (n = 3, black squares) in 0.5 mL
normal saline were injected intravenously. Arrows indicate the time
point of drug injection. *: p < 0.05 vs. vehicle. a. Mean arterial blood
pressure (MAP, mmHg). b. Hemorrhage volume in % of total blood
volume (%BV hemorrhage). c. Resuscitation fluid requirements (mL/kg)
to maintain MAP at 70 mmHg
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observation that a dose of 1 mg/kg of the linopirdine
analogue XE-991 was equally efficacious to reduce fluid
resuscitation requirements as a dose of 3 mg/kg of
linopirdine is consistent with the higher in vitro and in
vivo potency of XE-991 [26]. These findings suggest
that the fluid-sparing effects of linopirdine and XE-991
during resuscitation from hemorrhagic shock can be
considered as a general pharmacological property of
drugs that block Kv7 currents.
In an effort to optimize the dosing regimen, we then
tested resuscitation fluids supplemented with various
concentrations of linopirdine. As observed after single
bolus injection, linopirdine also dose-dependently re-
duced fluid requirements when used as a resuscitation
fluid supplement. The fluid-sparing effects of resuscita-
tion fluid supplemented with 12.5 μg/mL linopirdine
were comparable with the effects of a single 3 mg/kg
bolus injection of linopirdine at the beginning of fluid
resuscitation. Despite the similar efficacy of both dosing
regimens to reduce resuscitation fluid requirements,
supplementation of resuscitation fluid with linopirdine
reduced the cumulative linopirdine dose that was ad-
ministered during the experiment 7-fold to 0.45 mg/kg,
a dose of linopirdine that has no noticeable effects on
hemodynamics. Safety pharmacology testing of linopir-
dine has previously been performed in young and elderly
volunteers, who received oral doses of up to 55 mg [27].
Furthermore, linopirdine has been orally administered in
previous clinical trials in doses of 30 – 40 mg three
times per day for up to six months [15, 28]. Although
adverse effects on vital parameters were not noted in
these studies, elevated alanine transferase levels have
been described during oral administration of linopirdine
[15]. Information on the effects of linopirdine after intra-
venous administration in humans, however, is currently
not available. As Kv7 channels are abundantly expressed
in numerous vascular beds and tissues [10, 16], further
studies on possible side effects after intravenous linopir-
dine treatment are necessary. Nevertheless, we did not
observe toxicity associated with linopirdine treatment in
the present study, which is in agreement with previous
observations after intravenous linopirdine administration
in rodents [22, 24]. After oral administration in humans,
the half-life of linopirdine is 0.4 – 3.2 h [27]. After intra-
venous injection of 2.5 mg/kg linopirdine, a half-life of
0.6 h has been determined in rats [29]. Thus, the short
half-life would make linopirdine a drug that is easily
controllable if adverse effects would occur.
As the present pilot study was designed to provide ini-
tial pre-clinical evidence for a possible new indication
for the use of Kv7 channel blockers, we did not address
the in vivo mechanisms leading to reduced resuscitation
fluid requirements after hemorrhagic shock with Kv7
channel blockade. Nevertheless, one possible explanation
is that Kv7 channel blockade could sensitize vascular
smooth muscle function upon exposure to endogenous
vasoconstrictors during the cardiovascular stress response
Fig. 4 Supplementation of resuscitation fluids with linopirdine reduces
resuscitation fluid requirements after hemorrhagic shock. Animals were
hemorrhaged to a mean arterial blood pressure (MAP) of 25 mmHg for
30 min, followed by fluid resuscitation to a MAP of 70 mmHg. At the
end of the shock period (t = 30 min), animals were resuscitated with
normal saline (NS, vehicle, n = 4, open circles) or NS supplemented with
1.25 (n = 4,open squares), 6.25 (n = 3, light grey squares), 12.5 (n = 3,
dark grey squares) or 200 μg/mL (n = 6, black squares) linopirdine.
Arrows indicate the time point of drug injection. *: p < 0.05 vs. vehicle.
a. Mean arterial blood pressure (MAP, mmHg). b. Hemorrhage volume
in % of total blood volume (%BV hemorrhage). c. Resuscitation fluid
requirements (mL/kg) to maintain MAP at 70 mmHg
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after hemorrhagic shock. Alternatively, Kv7 channel block-
ade could reduce third-spacing of fluids during resuscita-
tion from hemorrhagic shock. Mechanistic in vivo studies
will be required to dissect the underlying mechanisms in
the future.
Conclusions
In conclusion, our findings point towards Kv7 channel in-
hibition as a new pharmacological approach to stabilize
hemodynamics and reduce fluid resuscitation requirements
after hemorrhagic shock. Although the short resuscitation
period limits the scope of our pilot study, our observations
provide proof of principle for a new indication for Kv7
channel blockers and initial information on the dose-effect
relationship for linopirdine. The findings from the present
study justify a more detailed pre-clinical evaluation of the
therapeutic efficacy and possible side-effect profile of lino-
pirdine after traumatic and hemorrhagic shock over longer
time periods. Such studies on the re-purposing of linopir-
dine for the treatment of trauma patients could lead to a
rapid transition into the clinical arena.
Abbreviations
%BV: % of total blood volume; BP: Blood pressure; DBP: Diastolic arterial
blood pressure; HR: Heart rate; MAP: Mean arterial blood pressure; NS: Normal




This research was supported by the National Institute of General Medical
Sciences (Awards R01GM107495 and T32GM008750) of the National Institutes
of Health. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
SPN, KLB and MM conceived and designed experiments. SPN performed
experiments. MM wrote the manuscript. SPN, KLB and MM reviewed and
commented on the manuscript and approved the final version.
Competing interests
Based on the results of this study, Loyola University Chicago has filed a
provisional patent application. SPN, KLB and MM are the inventors.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All procedures involving animals were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals, 8th Edition and were
approved by the Institutional Animal Care and Use Committee of Loyola
University Chicago (#LU3204797).
Received: 24 October 2016 Accepted: 10 January 2017
References
1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths:
final data for 2006. Natl Vital Stat Rep. 2009;57(14):1–134.
2. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma
outcome: an overview of epidemiology, clinical presentations, and
therapeutic considerations. J Trauma. 2006;60(6 Suppl):S3–11.
3. Smith JB, Pittet JF, Pierce A. Hypotensive Resuscitation. Curr Anesthesiol
Rep. 2014;4(3):209–15.
4. Madigan MC, Kemp CD, Johnson JC, Cotton BA. Secondary abdominal
compartment syndrome after severe extremity injury: are early, aggressive
fluid resuscitation strategies to blame? J Trauma. 2008;64(2):280–5.
5. Bougle A, Harrois A, Duranteau J. Resuscitative strategies in traumatic
hemorrhagic shock. Ann Intensive Care. 2013;3(1):1.
6. Malbrain ML, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ,
Van Regenmortel N. Fluid overload, de-resuscitation, and outcomes in
critically ill or injured patients: a systematic review with suggestions for
clinical practice. Anaesthesiol Intensive Ther. 2014;46(5):361–80.
7. Cohn SM, Blackbourne LH, Landry DW, Proctor KG, Walley KR, Wenzel V.
San Antonio Vasopressin in Shock Symposium report. Resuscitation. 2010;
81(11):1473–5.
8. Anand T, Skinner R. Arginine vasopressin: The future of pressure-support
resuscitation in hemorrhagic shock. J Surg Res. 2012;178(1):321–9.
9. Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels:
physiological regulators and new targets for therapeutic intervention. Mol
Pharmacol. 2008;74(5):1171–9.
10. Haick JM, Byron KL. Novel treatment strategies for smooth muscle disorders:
Targeting Kv7 potassium channels. Pharmacol Ther. 2016;165:14–25.
11. Miceli F, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology
and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin
Pharmacol. 2008;8(1):65–74.
12. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as
therapeutic targets. Nat Rev Drug Discov. 2009;8(12):982–1001.
13. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical
pharmacology. J Anaesthesiol Clin Pharmacol. 2012;28(2):172–7.
14. Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents
approved for the treatment of refractory partial seizures: ezogabine
(retigabine) and perampanel. Expert Opin Drug Saf. 2013;12(6):847–55.
15. Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W,
Gauthier S. A randomized, controlled trial of linopirdine in the treatment of
Alzheimer's disease. Can J Neurol Sci. 1997;24(2):140–5.
16. Stott JB, Jepps TA, Greenwood IA. K(V)7 potassium channels: a new therapeutic
target in smooth muscle disorders. Drug Discov Today. 2014;19(4):413–24.
17. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-
dose, linear, dose-proportional pharmacokinetics of retigabine in healthy
volunteers. J Clin Pharmacol. 2002;42(2):175–82.
18. Fretwell LV, Woolard J. Cardiovascular responses to retigabine in conscious
rats–under normotensive and hypertensive conditions. Br J Pharmacol.
2013;169(6):1279–89.
19. Morecroft I, Murray A, Nilsen M, Gurney AM, MacLean MR. Treatment with
the Kv7 potassium channel activator flupirtine is beneficial in two
independent mouse models of pulmonary hypertension. Br J Pharmacol.
2009;157(7):1241–9.
20. Sedivy V, Joshi S, Ghaly Y, Mizera R, Zaloudikova M, Brennan S, Novotna J,
Herget J, Gurney AM. Role of Kv7 channels in responses of the pulmonary
circulation to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2015;308(1):L48–57.
21. Bach HH, Wong YM, Tripathi A, Nevins AM, Gamelli RL, Volkman BF, Byron
KL, Majetschak M. Chemokine (C-X-C motif) receptor 4 and atypical
chemokine receptor 3 regulate vascular alpha(1)-adrenergic receptor
function. Mol Med. 2014;20:435–47.
22. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE,
Byron KL. Vascular KCNQ potassium channels as novel targets for the
control of mesenteric artery constriction by vasopressin, based on studies in
single cells, pressurized arteries, and in vivo measurements of mesenteric
vascular resistance. J Pharmacol Exp Ther. 2008;325(2):475–83.
23. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM. KCNQ modulators reveal a
key role for KCNQ potassium channels in regulating the tone of rat
pulmonary artery smooth muscle. J Pharmacol Exp Ther. 2009;329(1):368–76.
24. Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel
(KCNQ) opener retigabine in freely moving, conscious rats. J Urol. 2004;
172(5 Pt 1):2054–8.
25. Sakakibara K, Feng GG, Li J, Akahori T, Yasuda Y, Nakamura E, Hatakeyama N,
Fujiwara Y, Kinoshita H. Kynurenine causes vasodilation and hypotension
induced by activation of KCNQ-encoded voltage-dependent K(+) channels.
J Pharmacol Sci. 2015;129(1):31–7.
Nassoiy et al. Journal of Biomedical Science  (2017) 24:8 Page 7 of 8
26. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR,
Fisher BN, Rominger DH, Earl RA. Two new potent neurotransmitter release
enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-
bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to
linopirdine. J Pharmacol Exp Ther. 1998;285(2):724–30.
27. Pieniaszek Jr HJ, Fiske WD, Saxton TD, Kim YS, Garner DM, Xilinas M, Martz R.
Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996)
in healthy young adults and elderly volunteers. J Clin Pharmacol.
1995;35(1):22–30.
28. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, Arnsten AF,
Hoffer PB. The acetylcholine releaser linopirdine increases parietal regional
cerebral blood flow in Alzheimer's disease. Psychopharmacology (Berl).
1997;132(3):217–26.
29. Rakestraw DC, Bilski DA, Lam GN. Determination of linopirdine and its N-
oxide metabolites in rat plasma by liquid chromatography. J Pharm Biomed
Anal. 1994;12(8):1055–61.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nassoiy et al. Journal of Biomedical Science  (2017) 24:8 Page 8 of 8
